Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009

2008200720062004

2017 Archives

Dec 21, 2017
--Brings More Than 25 Years of Broad Pharmaceutical Industry Experience, Including Leadership Positions at Cipla, Teva, Dr. Reddy's and Bristol-Myers Squibb--

Lannett Company, Inc. (NYSE: LCI) today announced that its board of directors has named Timothy C. Crew as the company's chief executive officer (CEO), effective January 2, 2018. The Board of...

More
Dec 11, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2017 Prescription for Success Healthcare Conference on December 14, 2017 at 3:30 p.m....

More
Dec 1, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride (HCl) Topical Solution, 4% and 10%, with a proposed trade name of...

More
Nov 29, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Aralez Pharmaceuticals Trading DAC, an Irish designated activity company, to become the exclusive...

More
Nov 9, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies London Healthcare Conference on November 15, 2017 at 12:40 p.m. (GMT). A webcast of the...

More
Nov 6, 2017

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 first quarter ended September 30, 2017. "In recent weeks, we announced a number of very positive developments...

More
Nov 1, 2017

Lannett Company, Inc. (NYSE: LCI) today responded to the allegations in the amended civil complaint by a number of states' attorneys general pending in the U.S. District Court for the Eastern...

More
Oct 30, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S....

More
Oct 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 first quarter on Monday, November 6, 2017, after the market closes. Lannett management...

More
Oct 2, 2017
--Company Cleared to Market Prescription and OTC Generic Prevacid®--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lansoprazole...

More
Sep 27, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone and...

More
Sep 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dexmethylphenidate...

More
Sep 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the United States District Judge for the Eastern District of Pennsylvania dismissed in its entirety a putative class action lawsuit against a...

More
Sep 25, 2017
--CEO Arthur Bedrosian to Step Down Upon Naming of a Successor--

Lannett Company, Inc. (NYSE: LCI) today announced that its board of directors has begun a search for a new chief executive officer (CEO). As part of the unanimously approved search process, the...

More
Sep 22, 2017

Arthur Bedrosian, chief executive officer of Lannett Company, Inc. (NYSE: LCI), has prevailed in his lawsuit with the U.S. Internal Revenue Service (IRS). Bedrosian filed a lawsuit against the...

More
Sep 5, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Esomeprazole...

More
Aug 23, 2017

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "In the coming year, we expect a solid increase in net...

More
Aug 8, 2017
--Company to Report Full Financial Results and Host Conference Call on August 23--

Lannett Company, Inc. (NYSE: LCI) today reported preliminary financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "While our industry is currently facing...

More
Aug 1, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 37th Annual Growth Conference on August 9, 2017 at 4 p.m. (ET) at the InterContinental Hotel in

More
Jul 17, 2017

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Samuel H. Israel as vice president, chief legal officer and general counsel. "I am very pleased to welcome Sam to the Lannett...

More
Jul 14, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine...

More
Jun 26, 2017
--New Dosage Strengths of 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg Represent Lion's Share of the Market and Complement Previously Approved Dosage Strengths--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 22, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 20, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that Patrick G. LePore has been appointed to the company's Board of Directors, effective July 1, 2017. The addition of LePore will increase the...

More
Jun 19, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Niacin...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products